Cover Image
市場調查報告書

骨壞死:開發平台分析

Osteonecrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255968
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
骨壞死:開發平台分析 Osteonecrosis - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 40 Pages
簡介

骨壞死是骨骼供血不足所引起的狀態。最常見於骨盤及肩骨,膝蓋、手肘、手掌及腳等其他大關節也會發生。可能因為疾病、骨折及脫臼、影響血液流入骨骼的外傷所造成。初期階段沒有特別症狀,對症療法有效。

本報告提供骨壞死的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

骨壞死概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

開發治療藥的企業

  • Bone Therapeutics SA
  • Enzo Biochem, Inc.
  • K-Stemcell Co., Ltd.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最新的開發平台資訊

開發暫停中的計劃

產品開發的里程碑

  • 注目資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8699IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.Osteonecrosis.

Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteonecrosis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteonecrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteonecrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteonecrosis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteonecrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteonecrosis Overview
  • Therapeutics Development
    • Pipeline Products for Osteonecrosis - Overview
  • Osteonecrosis - Therapeutics under Development by Companies
  • Osteonecrosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Osteonecrosis - Products under Development by Companies
  • Osteonecrosis - Companies Involved in Therapeutics Development
    • Bone Therapeutics SA
    • Enzo Biochem Inc
    • K-Stemcell Co Ltd
  • Osteonecrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LWnt-3a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PREOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Osteonecrosis - Dormant Projects
  • Osteonecrosis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
      • Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR
      • May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
      • Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB
      • Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone
      • Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy
      • Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Osteonecrosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Osteonecrosis - Pipeline by Bone Therapeutics SA, H2 2016
  • Osteonecrosis - Pipeline by Enzo Biochem Inc, H2 2016
  • Osteonecrosis - Pipeline by K-Stemcell Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteonecrosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Osteonecrosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top